Skip to content

Study · Not a test of the peptide alone · 2019

3 results

Effects of combining modern recovery techniques with neurotrophic medication and standard treatment in stroke patients.

Uivarosan D, Tit DM, Iovan C, Nistor-Cseppento DC, Endres L, Lazar L, Sava C, Sabau AM, Buhas C, Moleriu LC, Bungau S, Aleya L

The Science of the total environment7 May 2019Cited by 16 (Europe PMC)

PMID31100563 (opens in a new tab)DOI10.1016/j.scitotenv.2019.05.070 (opens in a new tab)PepBankPUB-31100563
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone3

In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Cerebrolysin.

  1. 01HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome

    In stroke patients, associated therapies including Cerebrolysin showed significantly better overall improvement, especially during the first 6 months.

    In plain wordsIn stroke patients, combined therapies including Cerebrolysin showed better overall improvement than other study groups.

    Peptide
    Cerebrolysin
    Outcome
    IncreasePatient improvement
    Study

    n = 70

    Comparator
    Other study groups
    Outcome group
    Exercise and physical function · Nervous system and cognition

    Measurements

    P value for overall patient improvement
    < 0.05
    Associated therapies group versus other study groups, especially during the first 6 months

    Source sentences

    Summary
    Patient improvement is significantly better (p < 0.05) in the group with associated therapies, especially during the first 6 months.
    1 context sentence
    Summary · context
    a prospective study of 3 parallel groups was conducted: Group I (n = 22) - Lokomat, balneo-physiotherapy, and Cerebrolysin; Group II (n = 18) - Lokomat associated with balneo-physiotherapy; and Group III (n = 30) - balneo-physiotherapy alone (Control group).

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  2. 02HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome

    In stroke patients, all studied parameters were significantly better at 12 months than at baseline in all groups, including the group that also received Cerebrolysin.

    In plain wordsIn stroke patients, all measured outcomes were better at 12 months than at the start in every group, including the group that received Cerebrolysin.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseAll studied parameters at 12 months versus baseline
    Study

    n = 70

    Comparator
    Baseline
    Outcome group
    Exercise and physical function · Nervous system and cognition

    Measurements

    P value for all studied parameters
    < 0.05
    All groups at 12 months versus baseline

    Source sentences

    Summary
    Evolution was significantly better in all groups at 12 months than initially (p < 0.05), for all studied parameters and with the best effects in Group I (the three therapies combined).
    2 context sentences
    Summary · context
    Patients were evaluated physically, neurologically, and functionally, according to the evolution of their motor deficiency, spasticity, functional independence and health-related quality of life.
    Summary · context
    a prospective study of 3 parallel groups was conducted: Group I (n = 22) - Lokomat, balneo-physiotherapy, and Cerebrolysin; Group II (n = 18) - Lokomat associated with balneo-physiotherapy; and Group III (n = 30) - balneo-physiotherapy alone (Control group).

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

  3. 03HumanNot a test of Cerebrolysin aloneNon-randomized trialEfficacy outcome

    In stroke patients, all studied parameters improved at 12 months in all groups, with the best effects in the Lokomat, balneo-physiotherapy and Cerebrolysin group.

    In plain wordsIn stroke patients, the group with Lokomat, balneo-physiotherapy and Cerebrolysin showed the best improvement across all studied measures among the study groups.

    Peptide
    Cerebrolysin
    Outcome
    IncreaseAll studied parameters, best effects in Group I at 12 months
    Study

    n = 70

    Comparator
    Other study groups
    Outcome group
    Exercise and physical function · Nervous system and cognition

    Source sentences

    Summary
    Evolution was significantly better in all groups at 12 months than initially (p < 0.05), for all studied parameters and with the best effects in Group I (the three therapies combined).
    2 context sentences
    Summary · context
    Patients were evaluated physically, neurologically, and functionally, according to the evolution of their motor deficiency, spasticity, functional independence and health-related quality of life.
    Summary · context
    a prospective study of 3 parallel groups was conducted: Group I (n = 22) - Lokomat, balneo-physiotherapy, and Cerebrolysin; Group II (n = 18) - Lokomat associated with balneo-physiotherapy; and Group III (n = 30) - balneo-physiotherapy alone (Control group).

    In this study, Cerebrolysin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Cerebrolysin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.